KR100815042B1 - 이형접합성 가족성 고콜레스테롤혈증 치료에 있어서로수바스타틴(zd-4522)의 용도 - Google Patents

이형접합성 가족성 고콜레스테롤혈증 치료에 있어서로수바스타틴(zd-4522)의 용도 Download PDF

Info

Publication number
KR100815042B1
KR100815042B1 KR1020037006791A KR20037006791A KR100815042B1 KR 100815042 B1 KR100815042 B1 KR 100815042B1 KR 1020037006791 A KR1020037006791 A KR 1020037006791A KR 20037006791 A KR20037006791 A KR 20037006791A KR 100815042 B1 KR100815042 B1 KR 100815042B1
Authority
KR
South Korea
Prior art keywords
ldl
pharmaceutical composition
delete delete
dihydroxyhept
methylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020037006791A
Other languages
English (en)
Korean (ko)
Other versions
KR20030048479A (ko
Inventor
라자알리
허친슨하워드제라드
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100815042(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20030048479A publication Critical patent/KR20030048479A/ko
Application granted granted Critical
Publication of KR100815042B1 publication Critical patent/KR100815042B1/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020037006791A 2000-11-22 2001-11-16 이형접합성 가족성 고콜레스테롤혈증 치료에 있어서로수바스타틴(zd-4522)의 용도 Ceased KR100815042B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0028429.9A GB0028429D0 (en) 2000-11-22 2000-11-22 Therapy
GB0028429.9 2000-11-22
PCT/GB2001/005041 WO2002041895A1 (en) 2000-11-22 2001-11-16 Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia

Publications (2)

Publication Number Publication Date
KR20030048479A KR20030048479A (ko) 2003-06-19
KR100815042B1 true KR100815042B1 (ko) 2008-03-18

Family

ID=9903629

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037006791A Ceased KR100815042B1 (ko) 2000-11-22 2001-11-16 이형접합성 가족성 고콜레스테롤혈증 치료에 있어서로수바스타틴(zd-4522)의 용도

Country Status (34)

Country Link
US (1) US6858618B2 (cg-RX-API-DMAC7.html)
EP (1) EP1339409B1 (cg-RX-API-DMAC7.html)
JP (2) JP5062940B2 (cg-RX-API-DMAC7.html)
KR (1) KR100815042B1 (cg-RX-API-DMAC7.html)
CN (1) CN1268339C (cg-RX-API-DMAC7.html)
AR (1) AR031766A1 (cg-RX-API-DMAC7.html)
AT (1) ATE394103T1 (cg-RX-API-DMAC7.html)
AU (2) AU2002214165B9 (cg-RX-API-DMAC7.html)
BG (1) BG66009B1 (cg-RX-API-DMAC7.html)
BR (1) BR0115511A (cg-RX-API-DMAC7.html)
CA (1) CA2429263C (cg-RX-API-DMAC7.html)
CY (1) CY1110428T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ301583B6 (cg-RX-API-DMAC7.html)
DE (1) DE60133921D1 (cg-RX-API-DMAC7.html)
DK (1) DK1339409T3 (cg-RX-API-DMAC7.html)
EE (1) EE05507B1 (cg-RX-API-DMAC7.html)
ES (1) ES2305118T3 (cg-RX-API-DMAC7.html)
GB (1) GB0028429D0 (cg-RX-API-DMAC7.html)
HU (1) HUP0301380A3 (cg-RX-API-DMAC7.html)
IL (2) IL155919A0 (cg-RX-API-DMAC7.html)
IS (1) IS6819A (cg-RX-API-DMAC7.html)
MX (1) MXPA03004336A (cg-RX-API-DMAC7.html)
MY (1) MY134902A (cg-RX-API-DMAC7.html)
NO (1) NO326245B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ525754A (cg-RX-API-DMAC7.html)
PL (1) PL365386A1 (cg-RX-API-DMAC7.html)
PT (1) PT1339409E (cg-RX-API-DMAC7.html)
RU (1) RU2294744C2 (cg-RX-API-DMAC7.html)
SI (1) SI1339409T1 (cg-RX-API-DMAC7.html)
SK (1) SK6212003A3 (cg-RX-API-DMAC7.html)
TW (1) TWI238720B (cg-RX-API-DMAC7.html)
UA (1) UA75614C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002041895A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200303636B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260072167A (ko) 2024-11-13 2026-05-20 주식회사 종근당 텔미사르탄, 에스암로디핀, 로수바스타틴 및 에제티미브를 포함하는 약제학적 복합제제

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
SG182849A1 (en) * 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
EP1620109A2 (en) * 2003-04-25 2006-02-01 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7396927B2 (en) * 2003-08-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US7432273B2 (en) * 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005051921A1 (en) 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
CN1894221B (zh) * 2003-12-02 2012-08-08 特瓦制药工业有限公司 用于表征罗苏伐他汀的参照标准品
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
WO2005115377A1 (en) * 2004-05-26 2005-12-08 Kgk Synergize Inc Functional foods comprising flavonoids and tocotrienols and methods thereof
WO2006017357A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
PT2258376T (pt) 2004-07-27 2019-05-31 Gilead Sciences Inc Análogos fosfonatados de compostos inibidores do vih
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
TWI345562B (en) 2005-02-22 2011-07-21 Teva Pharma Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
KR20070062996A (ko) * 2005-08-16 2007-06-18 테바 파마슈티컬 인더스트리즈 리미티드 결정성 로수바스타틴 중간체
US9427437B2 (en) 2008-01-31 2016-08-30 The Trustees Of The University Of Pennsylvania Hypercholesterolemia and tendinous injuries
US8383614B2 (en) * 2008-01-31 2013-02-26 The Trustees Of The University Of Pennsylvania Hypercholestrolemia and tendinous injuries
EP2298745B1 (en) 2008-05-27 2014-09-03 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
BRPI0915878A2 (pt) 2008-07-08 2015-11-03 Gilead Sciences Inc sais ou hidratos de compostos inibidores de hiv, seu uso e composição farmacêutica que os compreende
ES2795450T3 (es) 2012-09-17 2020-11-23 Madrigal Pharmaceuticals Inc Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
PT3661937T (pt) 2017-08-01 2021-09-24 Gilead Sciences Inc Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais
KR20220029584A (ko) 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
WO2022165227A1 (en) * 2021-02-01 2022-08-04 Madrigal Pharmaceuticals, Inc. Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0521471A1 (en) * 1991-07-01 1993-01-07 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives as HMG-CoA reductase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2051907C1 (ru) * 1989-05-22 1996-01-10 Сандос АГ Способ получения 7-замещенной гептен-6-овой кислоты
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU6294501A (en) * 2000-09-20 2002-04-02 Rtp Pharma Inc Spray drying process and compositions of fenofibrate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0521471A1 (en) * 1991-07-01 1993-01-07 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives as HMG-CoA reductase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260072167A (ko) 2024-11-13 2026-05-20 주식회사 종근당 텔미사르탄, 에스암로디핀, 로수바스타틴 및 에제티미브를 포함하는 약제학적 복합제제

Also Published As

Publication number Publication date
JP2004522714A (ja) 2004-07-29
CZ20031406A3 (cs) 2003-09-17
NO20032292L (no) 2003-07-17
NO326245B1 (no) 2008-10-27
CZ301583B6 (cs) 2010-04-21
ZA200303636B (en) 2004-08-12
MXPA03004336A (es) 2003-08-19
MY134902A (en) 2007-12-31
SK6212003A3 (en) 2003-11-04
EE05507B1 (et) 2012-02-15
DE60133921D1 (de) 2008-06-19
GB0028429D0 (en) 2001-01-10
EE200300239A (et) 2003-08-15
AU1416502A (en) 2002-06-03
HUP0301380A2 (hu) 2003-10-28
IS6819A (is) 2003-05-19
IL155919A (en) 2009-09-01
UA75614C2 (uk) 2006-05-15
ES2305118T3 (es) 2008-11-01
NO20032292D0 (no) 2003-05-21
ATE394103T1 (de) 2008-05-15
DK1339409T3 (da) 2008-09-08
CA2429263A1 (en) 2002-05-30
WO2002041895A1 (en) 2002-05-30
HUP0301380A3 (en) 2007-03-28
JP2010031047A (ja) 2010-02-12
AU2002214165B9 (en) 2013-07-04
PT1339409E (pt) 2008-07-07
JP5062940B2 (ja) 2012-10-31
HK1056691A1 (en) 2004-02-27
BG107811A (bg) 2004-03-31
AU2002214165B2 (en) 2006-12-14
BG66009B1 (bg) 2010-10-29
IL155919A0 (en) 2003-12-23
BR0115511A (pt) 2003-12-30
TWI238720B (en) 2005-09-01
CN1630520A (zh) 2005-06-22
PL365386A1 (en) 2005-01-10
CA2429263C (en) 2009-03-17
SI1339409T1 (sl) 2008-08-31
EP1339409A1 (en) 2003-09-03
CY1110428T1 (el) 2015-04-29
KR20030048479A (ko) 2003-06-19
NZ525754A (en) 2004-10-29
US20040072852A1 (en) 2004-04-15
CN1268339C (zh) 2006-08-09
RU2294744C2 (ru) 2007-03-10
EP1339409B1 (en) 2008-05-07
US6858618B2 (en) 2005-02-22
AR031766A1 (es) 2003-10-01

Similar Documents

Publication Publication Date Title
KR20030048479A (ko) 이형접합성 가족성 고콜레스테롤혈증 치료에 있어서로수바스타틴(zd-4522)의 용도
AU2002214165A1 (en) Use of rosuvastatin (ZD-4522) in the treatment of heterozygous familial hypercholesterolemia
US5260305A (en) Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
CA2358632C (en) Drug combinations comprising (e)-7-¬4-(4-fluorophenyl)-6-isopropyl-2-¬methyl(methylsulfonyl)amino|pyrimidin-5-yl|(3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
JP2011137023A (ja) コレステロール低下薬の使用
US20070003636A1 (en) Statins (HMG-COA reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
KR20020086749A (ko) 베타 블록커 및 콜레스테롤 저하제의 신규한 조합물
JP2021535136A (ja) 心血管疾患及び関連する状態を有する患者を処置するための併用薬製剤
Shimpi et al. Bempedoic acid a novel drug used for the treatment of Hyperlipidaemia: A Review
HK1056691B (en) Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
HK1041817B (en) Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r, 5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
ZA200507614B (en) Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20030520

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20061115

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20071031

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20080221

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20080312

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20080312

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20110225

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20110225

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20120228

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20120228

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20130221

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20130221

Start annual number: 6

End annual number: 6

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Patent event date: 20130524

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20080312

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20130524

Decision date: 20150227

Appeal identifier: 2013100001360

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Patent event date: 20130702

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20080312

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20130702

Decision date: 20150227

Appeal identifier: 2013100001746

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Patent event date: 20130801

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20080312

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20130801

Decision date: 20150227

Appeal identifier: 2013100002053

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Patent event date: 20131106

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20080312

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20131106

Decision date: 20150227

Appeal identifier: 2013100002933

FPAY Annual fee payment

Payment date: 20140221

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20140221

Start annual number: 7

End annual number: 7

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Appeal kind category: Invalidation

Request date: 20140926

Decision date: 20150612

Appeal identifier: 2014100002411

Appeal kind category: Invalidation

Request date: 20140926

Decision date: 20150612

Appeal identifier: 2014100002409

Appeal kind category: Invalidation

Request date: 20140926

Decision date: 20150612

Appeal identifier: 2014100002407

Appeal kind category: Invalidation

Request date: 20140926

Decision date: 20150612

Appeal identifier: 2014100002405

Patent event date: 20140926

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20080312

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20140926

Decision date: 20150612

Appeal identifier: 2014100002403

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Appeal kind category: Invalidation

Request date: 20141027

Decision date: 20150612

Appeal identifier: 2014100002671

Appeal kind category: Invalidation

Request date: 20141027

Decision date: 20150612

Appeal identifier: 2014100002670

Appeal kind category: Invalidation

Request date: 20141027

Decision date: 20150612

Appeal identifier: 2014100002669

Appeal kind category: Invalidation

Request date: 20141027

Decision date: 20150612

Appeal identifier: 2014100002668

Appeal kind category: Invalidation

Request date: 20141027

Decision date: 20150612

Appeal identifier: 2014100002667

Appeal kind category: Invalidation

Request date: 20141027

Decision date: 20150612

Appeal identifier: 2014100002666

Appeal kind category: Invalidation

Request date: 20141027

Decision date: 20150612

Appeal identifier: 2014100002665

Appeal kind category: Invalidation

Request date: 20141027

Decision date: 20150612

Appeal identifier: 2014100002664

Patent event date: 20141027

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20080312

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20141027

Decision date: 20150612

Appeal identifier: 2014100002663

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Patent event date: 20141222

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20080312

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20141222

Decision date: 20150612

Appeal identifier: 2014100003291

FPAY Annual fee payment

Payment date: 20150224

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20150224

Start annual number: 8

End annual number: 8

J301 Trial decision

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20130524

Effective date: 20150227

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20130702

Effective date: 20150227

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20130801

Effective date: 20150227

Free format text: TRIAL NUMBER: 2013100001360; TRIAL DECISION FOR INVALIDATION REQUESTED 20130524

Effective date: 20150227

Free format text: TRIAL NUMBER: 2013100001746; TRIAL DECISION FOR INVALIDATION REQUESTED 20130702

Effective date: 20150227

Free format text: TRIAL NUMBER: 2013100002053; TRIAL DECISION FOR INVALIDATION REQUESTED 20130801

Effective date: 20150227

Free format text: TRIAL NUMBER: 2013100002933; TRIAL DECISION FOR INVALIDATION REQUESTED 20131106

Effective date: 20150227

PJ1301 Trial decision

Appeal kind category: Invalidation

Request date: 20131106

Decision date: 20150227

Appeal identifier: 2013100002933

Appeal kind category: Invalidation

Request date: 20130801

Decision date: 20150227

Appeal identifier: 2013100002053

Appeal kind category: Invalidation

Request date: 20130702

Decision date: 20150227

Appeal identifier: 2013100001746

Patent event code: PJ13011S05D

Patent event date: 20150227

Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design)

Appeal kind category: Invalidation

Request date: 20130524

Decision date: 20150227

Appeal identifier: 2013100001360

EXTG Ip right invalidated
PC2102 Extinguishment

Termination category: Others

Termination date: 20150616

Termination category: Others

Termination date: 20150514

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

Publication date: 20151104

J301 Trial decision

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20141027

Effective date: 20150612

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20140926

Effective date: 20150612

Free format text: TRIAL NUMBER: 2014100002403; TRIAL DECISION FOR INVALIDATION REQUESTED 20140926

Effective date: 20150612

Free format text: TRIAL NUMBER: 2014100002405; TRIAL DECISION FOR INVALIDATION REQUESTED 20140926

Effective date: 20150612

Free format text: TRIAL NUMBER: 2014100002407; TRIAL DECISION FOR INVALIDATION REQUESTED 20140926

Effective date: 20150612

Free format text: TRIAL NUMBER: 2014100002409; TRIAL DECISION FOR INVALIDATION REQUESTED 20140926

Effective date: 20150612

Free format text: TRIAL NUMBER: 2014100002411; TRIAL DECISION FOR INVALIDATION REQUESTED 20140926

Effective date: 20150612

Free format text: TRIAL NUMBER: 2014100002663; TRIAL DECISION FOR INVALIDATION REQUESTED 20141027

Effective date: 20150612

Free format text: TRIAL NUMBER: 2014100002664; TRIAL DECISION FOR INVALIDATION REQUESTED 20141027

Effective date: 20150612

Free format text: TRIAL NUMBER: 2014100002665; TRIAL DECISION FOR INVALIDATION REQUESTED 20141027

Effective date: 20150612

Free format text: TRIAL NUMBER: 2014100002666; TRIAL DECISION FOR INVALIDATION REQUESTED 20141027

Effective date: 20150612

Free format text: TRIAL NUMBER: 2014100002667; TRIAL DECISION FOR INVALIDATION REQUESTED 20141027

Effective date: 20150612

Free format text: TRIAL NUMBER: 2014100002668; TRIAL DECISION FOR INVALIDATION REQUESTED 20141027

Effective date: 20150612

Free format text: TRIAL NUMBER: 2014100002669; TRIAL DECISION FOR INVALIDATION REQUESTED 20141027

Effective date: 20150612

Free format text: TRIAL NUMBER: 2014100002670; TRIAL DECISION FOR INVALIDATION REQUESTED 20141027

Effective date: 20150612

Free format text: TRIAL NUMBER: 2014100002671; TRIAL DECISION FOR INVALIDATION REQUESTED 20141027

Effective date: 20150612

Free format text: TRIAL NUMBER: 2014100003291; TRIAL DECISION FOR INVALIDATION REQUESTED 20141222

Effective date: 20150612

PJ1301 Trial decision

Appeal kind category: Invalidation

Request date: 20141222

Decision date: 20150612

Appeal identifier: 2014100003291

Appeal kind category: Invalidation

Request date: 20141027

Decision date: 20150612

Appeal identifier: 2014100002671

Appeal kind category: Invalidation

Request date: 20141027

Decision date: 20150612

Appeal identifier: 2014100002670

Appeal kind category: Invalidation

Request date: 20141027

Decision date: 20150612

Appeal identifier: 2014100002669

Appeal kind category: Invalidation

Request date: 20141027

Decision date: 20150612

Appeal identifier: 2014100002668

Appeal kind category: Invalidation

Request date: 20141027

Decision date: 20150612

Appeal identifier: 2014100002667

Appeal kind category: Invalidation

Request date: 20141027

Decision date: 20150612

Appeal identifier: 2014100002666

Appeal kind category: Invalidation

Request date: 20141027

Decision date: 20150612

Appeal identifier: 2014100002665

Appeal kind category: Invalidation

Request date: 20141027

Decision date: 20150612

Appeal identifier: 2014100002664

Appeal kind category: Invalidation

Request date: 20141027

Decision date: 20150612

Appeal identifier: 2014100002663

Appeal kind category: Invalidation

Request date: 20140926

Decision date: 20150612

Appeal identifier: 2014100002411

Appeal kind category: Invalidation

Request date: 20140926

Decision date: 20150612

Appeal identifier: 2014100002409

Appeal kind category: Invalidation

Request date: 20140926

Decision date: 20150612

Appeal identifier: 2014100002407

Appeal kind category: Invalidation

Request date: 20140926

Decision date: 20150612

Appeal identifier: 2014100002405

Patent event code: PJ13011S05D

Patent event date: 20150612

Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design)

Appeal kind category: Invalidation

Request date: 20140926

Decision date: 20150612

Appeal identifier: 2014100002403

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

Publication date: 20151104

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

Publication date: 20151104

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

Publication date: 20151104